Enphase Energy Inc vs Revvity Inc — how do they compare? Enphase Energy Inc trades at $32.12 (market cap $4.35B), while Revvity Inc trades at $154.66 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 3.9× Enphase Energy Inc's market cap, and Revvity Inc pays a 0.18% dividend while Enphase Energy Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enphase Energy Inc for 72 Days and Revvity Inc for 12 Days on average.
| ENPH | RVTY | |
|---|---|---|
Market Cap | $4.35B | $16.98B |
Volume | 5,068,595 | 1,456,900 |
Sector | Energy | Health |
52-Week High | $72.33 | $157.36 |
52-Week Low | $26.12 | $82.26 |
Typical Hold Time | 72 Days | 12 Days |
Enterprise Value | $3.99B | $19.30B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
Enphase Energy (ENPH) trades at $32.095, down 4.19% with bearish technical signals. The stock shows mixed fundamentals with revenue declining from $2.3B in 2023 to $1.47B in 2025, though net income margin improved to 11.68%. Recent earnings show two misses in the last three quarters. Analyst sentiment is divided with 42% buy ratings but a consensus price target of $42.90 suggesting 34% upside. The company continues innovation with IQ Meter Collar approvals and solid-state transformer development for AI data centers.
The stock faces headwinds from solar industry pressures and elevated borrowing costs, but maintains strong gross margins and product innovation. With current price near support at $32 and significant upside to analyst targets, ENPH presents a contrarian opportunity for investors believing in the long-term solar growth story despite near-term volatility.
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →